Clinical management of MaBC remains profoundly challenging, with current therapeutic strategies largely extrapolated from female breast cancer protocols.<h4>Methods</h4>Through panel-based sequencing targeting <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> variants, we delineated the genomic landscape of 96 MaBC cases. This evidence concerns the gene BRCA2 and breast carcinoma.